Full history for every metric is available with a Kvantra account

Stock profile
BridgeBio Pharma, Inc. logo

BridgeBio Pharma, Inc. (BBIO)

Country: United States of AmericaSector: HealthcareIndustry: BiotechnologyExchange: NASDAQ
P/E TTM
N/A
History
P/E NTM
N/A
Market cap
14.81B
Currency USD
KvantraRankAbout22
IValue0
IIQuality46
IIIMomentum26
Current price
76.03 USD-2.75%
Close 20 Nov 2026
Interval
Benchmarks

Key financial summary

Financials in USD
202020212022202320242025TTM2026E
Total revenue$m8707892225029461,089
Operating profit$m-569-410
Net profit$m-449-563-481-643-536-729-570-479
EPS reported$-3.79-3.04
Operating cashflow per share$-2.26-1.88
Capex per share$0.010.03
FCF per share$-2.27-1.91
Free cash flow$m-447-374
Net debt$m2,141955
Book value equity$m-2,077-1,662
Book value per share$-10.53-8.48
Number of sharesm197.24196.03
DPS (TTM paid)$0.000.00

Financial summary

Financials in USD
202020212022202320242025TTM2026E
Value
P/E TTMx--
P/B LTMx-7.27-8.91
P/S LTMx30.0515.66
P/FCF LTMx-33.75-39.57
EV/EBITDA LTMx-25.49-35.80
EV/Sales LTMx34.3516.68
Earnings Yield LTM%-4.83%-3.73%
FCF Yield%-2.96%-2.53%
Quality
ROE%35.12%26.76%
ROIC%-108.46%-23.63%
Operating margin%-113.35%-43.35%
Gross margin%94.37%93.51%
FCF/Sales%-89.03%-39.59%
Growth and momentum
EPS Growth YoY%--
Sales Growth YoY%+126.26%+167.27%
Net Income Growth YoY%--
FCF Growth%--
Operating Profit Growth%--
Dividend and capital structure
Dividend Yield%0.00%0.00%
Dividend Growth%0.00%0.00%
Payout Ratio%--
FCF/Debtx-0.16-0.15
Net Debt/EBITDAx-3.19-2.18
EBIT/Net interestx-10.72-3.07
Net debt/market cap%14.19%6.45%
Net debt/Equityx-1.03-0.57
Gross debt/equityx-1.31-1.50

ETFs that hold BridgeBio Pharma

FundTickerPosition#Weight
Tema Heart & Health ETFHRTS63.68%

Funds with BridgeBio Pharma among their ten largest holdings, largest fund first.

Price target estimates

Low estimate
High estimate
Price consensus
Last year average price target
Current price76.03 USD
Return Potential

Based on consensus from external analysts. Not Kvantra's opinion.

Ratings

Strong Buy
Buy
Hold
Sell
Strong Sell
Number of covering analysts

Based on consensus from external analysts. Not Kvantra's opinion.

ESG

Metric202420252026
ESG-score
Environmental score
Social score
Governance score
Risk rating

Company overview

BridgeBio Pharma, Inc. is a pharmaceutical company dedicated to identifying, advancing, and providing medical solutions for various genetic conditions. The firm boasts an extensive portfolio comprising 30 distinct development initiatives, spanning the entire spectrum from initial discovery research to advanced clinical trial phases. Notable candidates within its development pipeline include: AG10 and BBP-265: A small molecule designed to stabilize transthyretin (TTR), currently in a pivotal Phase 3 clinical trial targeting transthyretin amyloidosis-cardiomyopathy (ATTR-CM). BBP-831: A selective small molecule inhibitor of FGFR1-3, which is undergoing Phase 2 clinical evaluation for treating achondroplasia in pediatric patients. BBP-631: An AAV5 gene transfer product candidate, also in Phase 2 clinical trials, aimed at congenital adrenal hyperplasia (CAH) caused by 21-hydroxylase deficiency (21OHD). Furthermore, BridgeBio is developing: Encaleret: A small molecule antagonist of the calcium sensing receptor (CaSR), presently in a Phase 2 proof-of-concept study for Autosomal Dominant Hypocalcemia Type 1 (ADH1). BBP-711: Intended for the management of hyperoxaluria and individuals prone to recurring kidney stones. Beyond these specific programs, the company is actively engaged in developing therapies for a broader range of Mendelian disorders, oncological diseases, and gene therapy applications. BridgeBio Pharma, Inc. maintains strategic licensing and collaboration agreements with institutions such as Leland Stanford Junior University, The Regents of the University of California, and Leidos Biomedical Research, Inc. Established in 2015, the company's corporate headquarters are situated in Palo Alto, California.

Trades inUSD

Similar companies

For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.

BridgeBio Pharma, Inc. (BBIO)

BBIO · NASDAQ · Healthcare
76.03 USD-2.75%
Sign up to track this stock
Benchmarks
KvantraRank22
Market cap14.81B
P/E NTMN/A
P/E TTMN/A
KvantraRank?22 / 100
Value
0
Quality
46
Momentum
26
Financialsin USD
20242025TTM2026E
ETFs that hold BridgeBio Pharma
FundTickerPosition#Weight
Tema Heart & Health ETFHRTS63.68%

Funds with BridgeBio Pharma among their ten largest holdings, largest fund first.

Analyst target
Consensus
Current76.03 USD
Upside
Price consensus
Last year average price target
Current price76.03 USD
Return Potential

Consensus from external analysts. Not Kvantra's opinion.

Ratings
Strong Buy
Buy
Hold
Sell
Strong Sell

Based on consensus from external analysts. Not Kvantra's opinion.

ESG
202420252026
ESG-score
Environmental score
Social score
Governance score
Risk rating
About

BridgeBio Pharma, Inc. is a pharmaceutical company dedicated to identifying, advancing, and providing medical solutions for various genetic conditions. The firm boasts an extensive portfolio comprising 30 distinct development initiatives, spanning the entire spectrum from initial discovery research to advanced clinical trial phases. Notable candidates within its development pipeline include: AG10 and BBP-265: A small molecule designed to stabilize transthyretin (TTR), currently in a pivotal Phase 3 clinical trial targeting transthyretin amyloidosis-cardiomyopathy (ATTR-CM). BBP-831: A selective small molecule inhibitor of FGFR1-3, which is undergoing Phase 2 clinical evaluation for treating achondroplasia in pediatric patients. BBP-631: An AAV5 gene transfer product candidate, also in Phase 2 clinical trials, aimed at congenital adrenal hyperplasia (CAH) caused by 21-hydroxylase deficiency (21OHD). Furthermore, BridgeBio is developing: Encaleret: A small molecule antagonist of the calcium sensing receptor (CaSR), presently in a Phase 2 proof-of-concept study for Autosomal Dominant Hypocalcemia Type 1 (ADH1). BBP-711: Intended for the management of hyperoxaluria and individuals prone to recurring kidney stones. Beyond these specific programs, the company is actively engaged in developing therapies for a broader range of Mendelian disorders, oncological diseases, and gene therapy applications. BridgeBio Pharma, Inc. maintains strategic licensing and collaboration agreements with institutions such as Leland Stanford Junior University, The Regents of the University of California, and Leidos Biomedical Research, Inc. Established in 2015, the company's corporate headquarters are situated in Palo Alto, California.

IndustryBiotechnology
Trades inUSD

For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.

Unlock all fundamental data

Sign up for Free

Unlock all fundamental data

Sign up for Free